Dyslipidaemias represent a major modifiable risk factor for atherosclerotic cardiovascular disease, a leading cause of morbidity and mortality worldwide.

This month’s FOCUS features resources centred around the new and revised recommendations from the 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias, reflecting the novel evidence available in the field .

These recommendations cover several aspects of lipid management including cardiovascular risk estimation, newer lipid-lowering drugs to lower LDL-cholesterol or triglycerides, lipid management during index hospitalisation for acute coronary syndromes, lipoprotein(a), management of people with HIV infection and patients receiving cardiotoxic cancer therapy, and the role of dietary supplements.

The content below was selected by Ronen Beeri, Maria Generosa Crespo Leiro, Konstantinos Koskinas, François Mach and Jeanine Roeters Van Lennep to help you delve into the various aspects of the 2025 Focused update of the 2019 ESC/EAS Guidelines for the management of dylipidaemias.